Scientists have discovered that the protein RPA (replication protein A) plays a key and so far unconfirmed role in stimulating telomerase, the enzyme that maintains the length of telomeres at the ends of chromosomes. RPA increases the processivity of telomerase, meaning it allows telomerase to lengthen telomeres more efficiently, preventing them from becoming dangerously shortened[1][7][8]. Disruptions or mutations in RPA lead to insufficient stimulation of telomerase, which causes telomere shortening and is associated with serious diseases such as telomere syndromes, including idiopathic pulmonary fibrosis and aplastic anemia[2][6]. RPA is a heterotrimeric protein that binds to single-stranded DNA at telomeres and cooperates with other proteins such as TPP1 to ensure proper telomerase function[1]. Research has shown that mutations in the TERT gene, which reduce the ability of RPA to stimulate telomerase, are associated with diseases caused by shortened telomeres[1]. A project focused on the study of RPA and its mutations, funded by the French agency ANR, confirmed that changes in RPA lead to telomere defects and are a genetic factor in telomere diseases[2]. These findings provide new molecular insights into the mechanisms of telomere maintenance and the causes of serious, mysterious diseases associated with telomere damage.